secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2025-09-10T23:59:59+00:00
Accession:  0001193125-25-199857
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma reports 33% ORR for rezatapopt in TP53 Y220C tumors; NDA for ovarian cancer planned Q1 2027
--------------------------------------------------------------------------------

- Overall ORR 33% (32/97 evaluable patients) across 8 tumor types; median duration of response 6.2 months.
- Ovarian cancer cohort: 43% ORR (19/44), median DOR 7.6 months, includes one confirmed complete response.
- Safety profile manageable: most TRAEs Grade 1-2, no discontinuations due to Grade 3 AST/ALT elevations, 3.7% discontinuation rate.
- FDA feedback supports NDA for platinum resistant/refractory ovarian cancer; plan to enroll 20-25 more patients by Q1 2026.
- NDA submission for rezatapopt in ovarian cancer targeted for end of Q1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000119312525199857/0001193125-25-199857-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000119312525199857/d90438d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-199857

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer